Novo Nordisk predicts milder growth in 2025 after obesity star Wegovy doubles sales in Q4

5th February 2025 Uncategorised 0

With sales of Novo Nordisk’s obesity blockbuster Wegovy more than doubling in 2024’s fourth quarter, the Danish drugmaker feels confident that it can maintain its edge over chief rival Eli Lilly in the year to come. Still, the company caveated that it expects sales growth in 2025 to be a bit milder than last year.

More: Novo Nordisk predicts milder growth in 2025 after obesity star Wegovy doubles sales in Q4
Source: fierce